key: cord-0695971-fozglfc8 authors: Song, Peipei; Li, Wei; Xie, Jianqin; Hou, Yanlong; You, Chongge title: Cytokine Storm Induced by SARS-CoV-2 date: 2020-06-10 journal: Clin Chim Acta DOI: 10.1016/j.cca.2020.06.017 sha: 422bcfff056d118337d3941c0afcb8b888142182 doc_id: 695971 cord_uid: fozglfc8 A novel coronavirus disease 2019 (COVID-19) triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently spreading globally, causing severe pneumonia and acute lung injury in many patients. Even worse, severe respiratory may develop into acute respiratory distress syndrome and multiple organ dysfunction syndrome in COVID-19. The cytokine storm caused by immune over-activation due to virus infection may be an important cause of death in the late period of progress, but the pathogenesis of cytokine storm is still unclear. This article reviews the mechanisms of SARS-CoV-2-induced cytokine storm in detail based on the current discovered researches, and put forward some valuable medication ideas for the targeted cytokines drug researches and treatment. The goal of this work will be helpful for reducing excessive immune response. In December 2019, the emergency of the novel coronavirus pneumonia in Wuhan China, posed a serious and urgent threat to the medical and health public in the world [1] . On 11 February 2020, the World Health Organization (WHO) officially named 2019-nCoV as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the disease caused by it as coronavirus disease 2019 . On 30 January 2020, the WHO declared COVID-19 as the sixth public health emergency of international concern, then on March 11, WHO made an assessment that COVID-19 can be characterized as a pandemic. It is the third highly pathogenic coronavirus emerged rapidly since SARS-CoV in 2003 and MERS-CoV in 2012 [2] , which made public health care institutions around the world face greater challenges. SARS-CoV-2 showed a similar pattern of infection, clinical features and even faster transmission rate [3] than the two coronaviruses have already erupted [4] . However, it is of particular attention that acute lung injury (ALI), systemic inflammatory response syndrome (SIRS), or acute respiratory distress syndrome (ARDS) occur in SARS-CoV or MERS-CoV infected patients, as well as in severe patients with COVID-19 [5] . Cytokines have been found that play a key role in driving the appearance of these clinical features and are also at the core of inflammation development [6, 7] . Consistent with the previous findings, severe COVID-19 patients showed significantly increased in cytokines such as IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A and TNFα, with the characteristics of a cytokine storm [8] . When SARS-CoV-2 infects the body, the inflammatory response plays an antiviral role, but the strong cytokine storm due to the unbalanced response will make a huge damage on patients. Therefore, taking some strategies to suppress effectively the cytokine storm is an essential way to prevent the deterioration of patients with COVID-19 and save the patients' lives, which is of great significance for the treatment of critically ill patients and reducing the mortality rate. In this review, SARS-CoV-2 and the occurrence mechanisms of cytokine storm induced by it will be introduced in detail, including the ways in which cytokines are activated and released, how they cause cell and organ damage, and therapeutic interventions to prevent or quell this harmful process. decreased (83.2%) [17] , and abnormally elevated ALT and AST [24, 25] , proinflammatory cytokines such as IL-1β, IL-6, and TNF-α increased, D-dimer, C-reactive protein (CRP), and procalcitonin (PCT) also increased [8] . In addition, patients' plasma angiotensin II (Ang II) levels were significantly increased, which was related to viral load and lung injury [24] . Clinical manifestations and pathology studies have shown that patients with COVID-19 mainly performed lung injury [26] , and most of the deaths due to multiple organ failure caused by ARDS [5, 27] . In addition, ICU patients showed higher levels of plasma cytokines, like IL-6 [28] , D-dimer, CRP, and PCT [29] , suggesting that inflammatory responses played a key role in these injuries, and may also be related to the severity of the patients [30] even the cause of death. Owing to the lack of direct evidence, it is unclear how the process of inflammatory response involved cytokines is fully completed, but it is certain that the manifested clinical features are directly related to the violent occurrence of inflammation. Cytokine storm refers to the overproduction of inflammatory cytokines that having a wide range of biological activity from a variety of tissues cells (mainly for immune cells), which due to different infection and a loss of negative feedback on the immune. In turn, those cytokines drive a positive feedback on others immune cells and continue to recruit them to the sites of inflammation, begetting the growing inflammation exponentially and organ damage. In short, it is the unceasing extreme activation and attack of the autoimmune system. The main cytokines involved are interleukin (IL), interferon (IFN), tumor necrosis factor (TNF), colony stimulating factor (CSF), chemokine family, growth factor (GF), etc. They are divided into pro-inflammatory factors (such as IL1β, IL6, IL12, TNF, IFNγ) and anti-inflammatory factors (such as IL4, IL10, IL13, TGFβ) based on their functions. Cytokine storms are a crucial cause of ARDS, systemic inflammatory response, and multiple organ failure [31] . Moreover, the viruses invade lung epithelial cells and alveolar macrophages to produce progeny nucleic acid which stimulate infected cells to release cytokines and chemokines, activating macrophages and dendritic cells etc [13] . Much more chemokines and cytokines are released from these cells to attract more inflammatory cells to migrate to the site of inflammation from the blood vessels, thereby cascading amplification the inflammatory response. It has long been believed that well-coordinated and rapid innate immune response is the first line of defense against viral infection. The cytokines synthesized and secreted by immune cells are involved in the induction period and effect phases in all inflammatory reactions, more importantly, activating the initiation of cytokine transcription mechanism to promote secretion is the key link. When immune cells in the body detect the pathogen-associated molecular pattern (PAMP) from the virus through the pattern recognition receptor (PRR) on the cell membrane, immediately, the innate immune response system is activated [32] . Among the PRRs, the most typical is Toll-like receptor (TLR3). TLR3 is a transmembrane receptor, extracellular accessory proteins MD-1, MD-2 and RP105 are involved in the recognition of PAMP [33] . Macrophages are the key cells for host defense. TLR3 on macrophages specifically recognizes the intermediate product ds-RNA of virus replication, followed by the recruitment recruits signal transfer proteins MyD88, TIRAP, TRAM or TRIF in the cytoplasmic TIR domain. Activation of various kinases (IRAKs, TBK1, and IKKs) and tumor necrosis factor receptor-related factor 6 (TRAF6) according to the different adaptors, eventually NF-κB, MAPK, or JNK-STAT pathways were activated to promote the transcription of inflammatory cytokines, and produce IFN, IL-1β and IL-6, etc., coordinating local or systemic inflammatory responses [34] (Figure 1 ). IL-1β and IL-6 are the major pro-inflammatory cytokines released during viral infections [35] . IL-1β enhances inflammatory responses of bronchia and alveolar in patients with lung injury. At the same time, acute phase proteins from hepatocytes stimulated by IL-1β and IL-6 activate the complement system, and the complement cascade further increases vascular permeability. PRR activates multiple cytokine transcription and delayed IFN-α and -β response IL-6 has always been an important star factor in cytokine storms. In virus-infected lesions, IL-6 can respond to IL-1, TNF-α, or TLR signals, trigger cis-regulatory modules, and activate the NF-κB transcriptional signaling pathway and the binding site of the nuclear factor IL-6 (CAAT/EBPβ) [36] . But the most important is that IL-6 combines with transmembrane receptor IL-6R to generate the IL-6/IL-6R complex. Then the signal transduction component gp130 dimerization induced by the complex, and activated Janus kinase signal transduction and transcription activators [37] (Figure 1 ). High levels of IL-6 can activate the coagulation system and increase vascular permeability, providing conditions for the rapid spread of inflammation [37] . As reported that higher levels of IL-6 in severe patients with COVID-19, which proves that high levels of IL-6 may cause greater damage to lung tissue [8] . It has been verified in vitro that SARS-CoV S protein induces upregulation of IL-6 and TNF-α in mouse macrophages through the NF-κB pathway [38] . The cytokine-mediated inflammatory response pathway is a series of intersecting networks, each one has a degree of redundancy and with alternate pathways. The combinations of TLR and ligands initiate signal cascaded amplification and lead to the activation of multiple cytokine pathways, which is the main research focus of current inflammatory responses. Through the regulation of cytokines and chemokines, conventional lymphocytes (T cells and B cells) differentiate into specific effector cells and localize at the site of infected. For instance, CD4+T cells differentiate into Th1 cells and produce IFN-γ to activate macrophages and other types of cells because of the induction of IL12, thereby triggering defense against intracellular pathogens. At the same time, IFN-γ can induce the transcription of multiple chemokines. Besides, IL-6 induce the differentiation of CD8+T cells into cytotoxic T cells, which eliminated the viruses in the way of lysing infected cells suicide. The consumption of cytotoxic T cells may be the cause of the decrease in lymphocytes in most patients with COVID-19 [8] . It has been found T lymphocytes are a vital source of many chemokines and express multiple molecule receptors [39] . Such as neutrophils and macrophages are drawn to the region of injury by IL-8 and MCP-1chemotactic influences, respectively, while secreting chemokines to recruit more cells to participate in the battle with pathogens. It is now accepted that each cell can respond to multiple chemokines just by expressing a single type of receptor. It is this complex relationship between chemokines and their receptors that makes chemokines rapidly replenish in various microenvironments, and the inflammatory storm continues to develop [35] . According a report, the proinflammatory cytokines like TNF, IL-6 and chemokines IL8, CCL3 (MCP-1), CCL5, CCL2 and CXCL10 were significantly up-regulated, while the anti-inflammatory factor such as IL10 was lacking in SARS patients [31] , which showed that the lack of anti-inflammatory factors can cause an imbalance in the inflammatory response and promote cytokine storm. Acute lung injury (ALI) is a common consequence of cytokine storm in lung tissue and systemic circulation [40] . Recently, pulmonary pathology of SARS-CoV-2 infection showed, the major changes of the lung tissue showed diffuse alveolar damage, alveolar edema and proteinaceous exudates, thickening of alveolar walls, evident desquamation of pneumocytes and hyaline membrane formation indicated ARDS [26] . And multinucleated giant cells in the alveolar cavity, inflammatory infiltration of lymphocytes in the pulmonary mesenchyme [27] . In addition, the patient's pathological results confirmed that the number of CD4+T and CD8+T cells in peripheral blood reduced but over-activated. The high proinflammatory effects Th17 cells increased that concentrating CCR4+/CCR6+, and CD8+T cells contain high concentrations of cytotoxic granules, mainly perforin and granulysin, which can cause severe immune damage in patients [27] . These evidences showed that patients with extensive acute lung injury and multiple organ failure, which may be caused by the activation of the body's immune system, including innate immunity and adaptive immunity, resulting in a strong inflammatory storm. Angiotensin converting enzyme 2 (ACE2) has been proved to be a cellular receptor for SARS-CoV-2 [41] . In addition, 21 mutations were found in the SARS-CoV-2 spike glycoprotein binding region, suggesting coronavirus evolved gradually for adapting to human hosts [42, 43] . Though ACE2 exists in various tissues such as coronary arteries, vascular endothelium, and renal tubular epithelium [44] , macrophages and pulmonary alveolar epithelial are mainly attacked targets [30] , which explains why contribute to acute lung injury mainly. Currently, it is generally believed that SARS-CoV-2 is considered susceptible to all populations. In animal models, it has been demonstrated that older rhesus monkeys are more susceptible to SARS-CoV [45] , and the up-express of ACE2 in the lower respiratory tract induced by smoking may increase sensitivity to SARS-CoV-2. Genetic analysis of ACE2 found that mutant expression was higher in East Asian populations, which may indicate that there are differences for SARS-CoV-2 infectivity among different populations [46] . In addition, rapid virus replication causes cell pyroptosis, immune evasion, and cell lysis triggered by anti-Fc antibodies, all of which trigger the release of mass pro-inflammatory cytokines and chemokines. Therefore, the COVID-19 patient's clinical symptoms exacerbated may be the result of a combination that cytopathic effects directly caused by the virus infection and immunopathology injury caused by violent cytokine storms. From the molecular modeling structural analysis results of 2019-nCoV receptors, the receptor binding domain (RBD) of SARS-CoV-2 has more effective interaction with ACE2 compared to SARS-CoV [47] . The binding of S protein to ACE2 is the first step for the virus to enter target cells, accomplished by proteolytic cleavage and fusion of the viral and cellular membranes [13] . It was speculated that SARS-CoV-2 might also cause lung tissue injury in the same pathogenic mechanism [48] . On the one hand, when SARS-CoV-2 infects alveolar cells, S1 and ACE2 transmembrane domains combine to reduce the level of ACE2, resulting in the Renin Angiotensin System (RAS) tilts towards the ACE-Ang II axis [49] . Meanwhile, the production of Ang II is absolutely or relatively elevated, which causing macrophagocyte infiltration, inducing cytokines and adhesion molecules increase, including IL-6, monocyte chemotactic protein 1 (MCP-1), vascular cell adhesion molecule 1 (VCAM-1), selectin E etc., causing endothelial dysfunction [50, 51] . Besides, down-regulation of ACE2 reduces protective effects against acute lung injury [49] , leading to increased pulmonary capillary permeability and pulmonary edema, and severe patients may die of respiratory failure. On the other hand, cell experiment studies in vitro have shown that SARS-CoV S induces shedding of the ACE2 extracellular ectodomain and promotes virus entry into cells through dependence on TNF-α converting enzyme (TACE). But the function of free sACE2 is unknown currently, which may also mediate inflammation and tissue injury [52] . In addition, the binding of virus and ACE2 might also be involved in intracellular pathway recognition. Pyroptosis is a new inflammatory form of programmed cell death, inflammation storms caused by SARS-CoV-2 infection may be related to cell pyroptosis. Research evidences from Chen et al. showed that SARS-CoV Viroporin 3a protein activates NLRP3 (NOD-like receptors protein 3) inflammasome causing IL-1β production [53] . Reduced cell counts and increased IL-1β in serum of COVID-19 patients may indicated activation of cell pyroptosis. When a variety of extracellular PAMPs are recognized by TLRs [54], which triggers activation of the NF-κB signaling pathway and upregulation of inflammasome related components, including inactivated NLRP3, proIL-1β, and proIL-18. Subsequently, NLRP3 oligomerize and it was connected with the pro-caspase-1 through the adaptor protein ASC to form a multiprotein complex, thereby activating caspase-1 [55] . Activated caspase-1 recruits and incises members of the polymerizes Gasdermin family such as GSDMD in the pathway downstream [56] , simultaneously, incises the precursors of IL-1β and IL-18 forming active IL-1β and IL18, which are released into the extracellular to recruit more inflammation cells to aggregate and expand the inflammatory response [57] . Besides, the active cleavage fragment of GSDMD caused extensive cell perforation by inserting into the lipid bilayer, resulting in cell swelling and lysis, which was followed by release of contents such as cellular matrix and cytokines [58] . A mass of endogenous molecules from immune intracellular are released, such as oxidized phospholipids and cellular matrix, which are called damage-associated molecular patterns (DAMP). Similar to PAMP known as alarm singles, they can also be recognized by NLRP3, thereby progressively magnify the inflammatory effects and cause cell pyroptosis [59] (Figure 2) . COVID-19 patients often have lymphopenia, but further research is still needed to prove whether it is also related to this mechanism. Intracellular signaling mechanism of cell pyroptosis induced by PAMPs IFN is a core family in innate antiviral immunity , type I interferons (IFN-α and -β) are essential especially for the innate immune response against viruses and other microbial infections. The binding of type I interferon and tis dimer receptor (IFNAR) activates the JAK-STAT signal transduction pathway, in which JAK1 and TYK2 kinases phosphorylate, STAT1, STAT2 and IRF9 form a complex. These complexes enter the nucleus and initiate the transcription of IFN-stimulated genes (ISG) [60] . In vitro studies have found that rapid replication of SARS-CoV in mice induces significant but delayed IFN-α/β response, accompanied by a large influx of pathogenic inflammatory mononuclear macrophages (IMM) [61] , leading to lung cytokines and chemokine increased, vascular leakage and virus-specific T cell apoptosis, further hinder virus clearance. In addition, studies have demonstrated that coronaviruses can rapidly replicate in host cells and encode proteins (NSP1) that antagonizes IFNs response by blocking STAT1 phosphorylation [13, 62] . Meanwhile, structural proteins M and N inhibit IFNs signaling by deactivating TRAF3, TBK1/IKKs, and some other mechanisms, respectively [63] . The coronavirus structural and nonstructural protein against the delayed response of IFNs further amplifies the inflammatory response by promoting viral replication, followed with the increase of viral PAMPs. In turn, the PAMPs inhibit delayed IFN signaling and stimulate PRR-induced abnormal inflammatory responses [64] . Above all, it should be clear that these putative antiviral mechanisms have been confirmed in stepby-step studies. Whether they are really important in infectious viruses and systemic antagonist pathways need to be further studied. Generally considered that antiviral antibodies play a much important role in the viral clearance. According to reports, the response to anti-S-neutralizing antibodies (NAb) in dead patients developed significantly faster (14.7 vs 20 days) and higher level than patients who had recovered during SARS [65] . In a SARS-CoV Macaque experimental model, inoculated with S protein antibody, it has been found that anti-S-IgG facilitate severe lung injury in the early stages of infection via eliminates wound healing macrophage response and TGF-β production as well as promote inflammatory macrophages and the production of factors MCP-1 and IL-8 [66] . These evidences suggested that anti-S-IgG may also play an important role in lung injury caused by acute SARS-CoV-2 infection during acute infection period [66] . Since FcR was blockaded reducing the production of inflammatory cytokines, it is considered that the virus-anti-S-IgG complex may promote cytokine release by binding to Fc receptors on the surface of macrophages, or additionally through antibody-dependent cell-mediated cytotoxicity (ADCC) directly lyses target cells [67] . Whether this complex is associated with antibody-dependent enhancement (ADE) [68] or complement system activation in patients with COVID-19 during viral replication [55] remains to be proven by further studies. In sum, the rapid spread of SARS-CoV-2 has forced all medical institutions to carry out research and prevention and control worldwide. All efforts are being made to slow the spread of COVID-19 in order to provide better public-health recommendations, and to develop timely diagnostics, therapeutics and vaccines. The mentioned above potential mechanisms are based on two outbreaks of coronavirus and current partial research [69] , many new mechanisms still unknown. New treatments are developed based on existing experience in combating viral infections. However, at present, treatment strategies for SARS-CoV-2 infection are only supportive, more important is no effective antiviral therapies for COVID-19. Here we assume and discuss that SARS-CoV-2 likely associate similar cytokines storm. Therapeutic interventions targeting these pro-inflammatory cytokines and chemokines may help alleviate adverse inflammatory responses. Corticosteroids are usually used to suppress inflammation responses, which were the main means of immunomodulatory therapy during the SARS epidemic. But the early patients were found increased plasma viral load and secondary infections [70] . In some studies, early administration of IFN is beneficial in reducing viral load and moderately improves clinical performance, and combination with ribavirin also made certain therapeutic effect [71] . IFN-λ inhibited the recruitment of inflammatory cells and the production of IL-1β without excessive stimulation for the immune system, which might become a potential therapeutic direction [72] . Besides, the results from the management of patients with COVID-19 by Xu et al, showed that an artificial liver blood purification system can quickly clear inflammation mediators to suppress cytokine storms, however, repair system may be delayed for excessive clarity [73] . However, these strategies still need to be tested for clinical effectiveness. In addition, there is evidence that the serine protease TMPRSS2 plays an important role in SARS-CoV-2 entry into cellular but TMPRSS2 inhibitors can prevent entry, this may become a treatment option. And more, SARS-CoV-2 was neutralized by serum from recovery SARS patients [41] , showing a good therapeutic effect. Therefore, the use of intravenous immunoglobulin may be a viable option for the urgent treatment of pulmonary inflammation, meanwhile, which means that vaccine development may be the most effective means, but current vaccine production faces many obstacles. This requires researchers to explore via international cooperation. Studies have found that there may be individual differences in susceptibility to cytokine storms. The innate immune response of healthy people is highly variable, which can be genetically confirmed the TLR receptor. For example, sepsis patients with single nucleotide polymorphisms (SNPs) of TLR1 hypermorphic variants, which is associated with increased susceptibility to organ dysfunction, death, and gram-positive bacteremia infection [74] . TLR4 is the major contributor to lipopolysaccharide (LPS), and its variants can make individuals susceptible to sepsis, genome-wide association studies (GWAS) have linked TLR4 polymorphisms to pathogen susceptibility and disease severity [35] . Future researches likely reveal potential genetic variations that affect host cytokine storms during infection. In addition, the body's immune pathological damage is closely related to the viral load, and the degree of the cytokine storm is an essential connection point. If plasma cytokines are monitored dynamically to assess the degree of cytokine storm, timely and effectively, which may be of great benefit to the care of critically ill patients. The inflammatory response is an essential part of the immune system to function, otherwise pathogen will be difficult to eliminate. SARS-CoV-2 might induce excessive and prolonged cytokine responses, resulting in lung damage and multiple organ failure. So far, most studies have focused on the direct measurement of those cytokines and chemokines in peripheral blood, but in the context of the rapidly changing cytokine environment after virus infection, we have no round understanding the cause of the vigorous inflammatory response. A comprehensive understanding of the factors. Although existing researches have shown that during the occurrence of pathogenic hCOV infection, the violent cytokine storm, caused immune pathological damage and may be the real "dead killer" in critically ill patients. At the same time, human autopsy and animal models studies provided some evidences for the pathogenic mechanism of inflammatory cytokines, derived from IMM and neutrophils. However, current researches are limited, and detailed molecular biology principles and broader epidemiology are lacking. Therefore, future researches should not only focus on the identification of specific inflammatory response signaling pathways, in patients and animals infected with hCoV, but of course, include the scientific and effective application to control the spread of the virus worldwide. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. A Novel Coronavirus from Patients with Pneumonia in China Return of the Coronavirus: 2019-nCoV Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures The reproductive number of COVID-19 is higher compared to SARS coronavirus Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: epidemiology, pathogenesis and clinical characteristics Clinical features of patients infected with 2019 novel coronavirus in Tracing the SARS-coronavirus Host Factors in Coronavirus Replication Coronavirus envelope protein: current knowledge The molecular biology of coronaviruses Coronaviruses: an overview of their replication and pathogenesis Origin and evolution of pathogenic coronaviruses A pneumonia outbreak associated with a new coronavirus of probable bat origin Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV Clinical Characteristics of Coronavirus Disease 2019 in China Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2 Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury Exploring the mechanism of liver enzyme abnormalities in patients with novel coronavirus-infected pneumonia Pulmonary Pathology of Early-Phase Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer Pathological findings of COVID-19 associated with acute respiratory distress syndrome Clinical characteristics of laboratory confirmed positive cases of SARS-CoV-2 infection in Wuhan, China: A retrospective single center analysis Clinical characteristics of 140 patients infected with SARS-CoV-2 in Multiple organ infection and the pathogenesis of SARS The clinical pathology of severe acute respiratory syndrome (SARS): a report from China Recognition of microorganisms and activation of the immune response Toll-like receptor signaling Intracellular pattern recognition receptors in the host response Into the eye of the cytokine storm IL-6 in inflammation, immunity, and disease, Cold Spring Harbor perspectives in biology Immunotherapeutic implications of IL-6 blockade for cytokine storm Upregulation of IL-6 and TNF-alpha induced by SARS-coronavirus spike protein in murine macrophages via NF-kappaB pathway, Virus research Chemokines: understanding their role in T-lymphocyte biology Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Molecular Evolution of Human Coronavirus Genomes Identification of the hyper-variable genomic hotspot for the novel coronavirus SARS-CoV-2 A novel angiotensin-converting enzymerelated carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9 Exacerbated innate host response to SARS-CoV in aged non-human primates Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations Structure analysis of the receptor binding of 2019-nCoV A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury Angiotensin-converting enzyme 2 protects from severe acute lung failure Xia, CX3CL1/CX3CR1 Axis Contributes to Angiotensin II-Induced Vascular Smooth Muscle Cell Proliferation and Inflammatory Cytokine Production Angiotensin II-Induced Early and Late Inflammatory Responses Through NOXs and MAPK Pathways Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry Severe Acute Respiratory Syndrome Coronavirus Viroporin 3a Activates the NLRP3 Inflammasome The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation Pyroptosis: Gasdermin-Mediated Programmed Necrotic Cell Death Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages, Cellular microbiology Key Role of DAMP in Inflammation, Cancer, and Tissue Repair SARS and MERS: recent insights into emerging coronaviruses Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice Severe acute respiratory syndrome coronavirus nsp1 suppresses host gene expression, including that of type I interferon, in infected cells Suppression of innate antiviral response by severe acute respiratory syndrome coronavirus M protein is mediated through the first transmembrane domain Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals Antispike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools Is COVID-19 receiving ADE from other coronaviruses? Insights into the Recent Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study Coronaviruses -drug discovery and therapeutic options IFN-λ resolves inflammation via suppression of neutrophil infiltration and IL-1β production Management of corona virus disease-19 (COVID-19): the Zhejiang experience Toll-like receptor 1 polymorphisms affect innate immune responses and outcomes in sepsis This work was supported by Science and Technology Plan Project of Gansu (grant no. 18YF1FA108), Lanzhou University Second Hospital Cuiying Fund Project (grant no. CY2018-MS10), and National Natural Science Foundation of China (grant no. 81560343).